These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11156341)

  • 1. The monoethylglycinexylidide (MEGX) test as a marker of hepatic dysfunction in septic patients with pneumonia.
    Igonin AA; Armstrong VW; Shipkova M; Kukes VG; Oellerich M
    Clin Chem Lab Med; 2000 Nov; 38(11):1125-8. PubMed ID: 11156341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Monoethylglycinexylidide--a metabolite of lidocaine--as an index of liver function in chronic hepatic parenchymal diseases].
    Kupcová V; Turecký L; Szántová M; Schmidtová K
    Bratisl Lek Listy; 1999 Jan; 100(1):12-24. PubMed ID: 10492993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MEGX test: a tool for the real-time assessment of hepatic function.
    Oellerich M; Armstrong VW
    Ther Drug Monit; 2001 Apr; 23(2):81-92. PubMed ID: 11294522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of an extended monoethylglycinexylidide formation test and other dynamic liver function tests in liver transplant donors.
    Zotz RB; von Schönfeld J; Erhard J; Breuer N; Lange R; Beste M; Goebell H; Eigler FW
    Transplantation; 1997 Feb; 63(4):538-41. PubMed ID: 9047147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of monoethylglycinexylidide as measure of liver function for patients with chronic viral hepatitis.
    Elin RJ; Fried MW; Sampson M; Ruddel M; Kleiner DE; DiBisceglie AM
    Clin Chem; 1997 Oct; 43(10):1952-7. PubMed ID: 9342018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lidocaine (MEGX) test as an index of hepatic function: its clinical usefulness in liver surgery.
    Ercolani G; Grazi GL; Callivà R; Pierangeli F; Cescon M; Cavallari A; Mazziotti A
    Surgery; 2000 Apr; 127(4):464-71. PubMed ID: 10776439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoethylglycinexylidide (MEGX) as a liver function test in cirrhosis.
    Bhise SB; Dias RJ
    Indian J Gastroenterol; 2007; 26(4):167-9. PubMed ID: 17986743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.
    Wojcicki J; Kozlowski K; Drozdzik M; Wojcicki M
    Eur J Drug Metab Pharmacokinet; 2002; 27(4):243-7. PubMed ID: 12587953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Multiple organ failure after severe trauma: predictable by the MEGX liver function test?].
    Pape D; Lehmann U; Oellerich M; Regel G
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():338-9. PubMed ID: 9101869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lidocaine metabolite formation as a measure of perioperative liver function.
    Shimanuki K; Sakurabayashi I; Miyata M; Kiyozaki H; Suzuki W; Kashii A; Seo N
    Surg Today; 1993; 23(4):315-9. PubMed ID: 8318785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endotoxic shock alters the pharmacokinetics of lidocaine and monoethylglycinexylidide.
    McKindley DS; Boulet J; Sachdeva K; Wang P; Chichester C
    Shock; 2002 Mar; 17(3):199-204. PubMed ID: 11900338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the monoethylglycinexylidide (MEGX)-test prior to liver resection.
    Lorf T; Schnitzbauer AA; Schaefers SK; Scherer MN; Schlitt HJ; Oellerich M; Becker H; Obed A
    Hepatogastroenterology; 2008; 55(82-83):539-43. PubMed ID: 18613404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The unreliability of the lidocaine/monoethylglycinexylidide test for assessment of liver donors.
    Reding R; Wallemacq P; de Ville de Goyet J; Lerut J; Hausleithner V; Feyaerts A; Lambotte L; Otte JB
    Transplantation; 1993 Aug; 56(2):323-6. PubMed ID: 8356585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of 4% topical lidocaine applied to the face on the serum levels of lidocaine and its metabolite, monoethylglycinexylidide.
    Oni G; Brown S; Burrus C; Grant L; Watkins J; Kenkel M; Barton F; Kenkel J
    Aesthet Surg J; 2010; 30(6):853-8. PubMed ID: 21131461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of dopamine-induced changes in splanchnic blood flow on MEGX production from lidocaine in septic and cardiac surgery patients.
    Jakob SM; Ruokonen E; Rosenberg PH; Takala J
    Shock; 2002 Jul; 18(1):1-7. PubMed ID: 12095126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring lidocaine metabolite--monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis.
    Huang YS; Lee SD; Deng JF; Wu JC; Lu RH; Lin YF; Wang YJ; Lo KJ
    J Hepatol; 1993 Aug; 19(1):140-7. PubMed ID: 8301034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoethylglycinexylidide production as a measure in predicting hepatic histology.
    Forte G; Rocco P; Costanzo A; Grimaldi E; Rossi R; Bottiglieri ME; Biceglia O; Zampella G
    Ital J Gastroenterol; 1994 May; 26(4):159-62. PubMed ID: 7949258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of lidocaine metabolite (monoethylglycinexylidide) as a liver function test].
    Shimanuki K; Suzuki W; Sakurabayashi I; Kiyozaki H; Shinohara K; Soda K; Kai T; Satake M; Miyata M
    Nihon Shokakibyo Gakkai Zasshi; 1993 Jan; 90(1):33-40. PubMed ID: 8433534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liver function and splanchnic ischemia in critically ill patients.
    Maynard ND; Bihari DJ; Dalton RN; Beale R; Smithies MN; Mason RC
    Chest; 1997 Jan; 111(1):180-7. PubMed ID: 8996014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The monoethylglycinexylidide test for grading of liver cirrhosis.
    Fabris L; Jemmolo RM; Toffolo G; Paleari D; Viaggi S; Rigon M; Casagrande F; Lirussi F; Strazzabosco M; Cobelli C; Okolicsanyi L
    Aliment Pharmacol Ther; 1999 Jan; 13(1):67-75. PubMed ID: 9892881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.